Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)
(“Diffusion” or “Company”) announces the submission of a Clinical
Trial Application (CTA) to the Romanian National Agency for
Medicines and Medical Devices (NAMMD) to initiate a Phase 1a/1b
clinical trial of the Company's novel oxygenation-enhancing product
candidate trans sodium crocetinate (TSC) for the treatment of
hospitalized COVID-19 patients displaying severe respiratory
symptoms and low oxygen levels. Low oxygen levels occur as a
consequence of damage to the lungs from COVID-19 and often result
in mechanical ventilation and, if that is ineffective, multiple
organ failure – the leading cause of death in COVID-19 patients.
Assuming NAMMD authorization of the CTA and
approval by the National ethics committee under NAMMD’s accelerated
seven-working-day approval process, Diffusion plans to begin the 24
patient Phase 1a portion of the clinical trial by the end of Q2
2020. The entire Phase 1a/1b trial will enroll approximately
224 patients and is expected to last approximately 12 months.
First data readout on the initial 24 patients is expected in Q3
2020, followed by an interim readout on 50 patients in Q4 2020 and
final data in Q2 2021.
This first European study will be facilitated by
ARENSIA Exploratory Medicine GmbH and conducted at the National
Institute of Infectious Diseases (NIID), Bucharest, Romania, with
the Institute’s Managing Director, noted infectious diseases
researcher Prof. Adrian Streinu-Cercel, M.D. PhD., serving as
Principal Investigator. The 1a phase will be an open-label,
pharmacokinetic/ pharmacodynamic, dose-finding, safety lead-in
study testing TSC in 24 hospitalized, non-ventilated COVID-19
patients with documented oxygen deficiency.
Upon completion and readout of the 1a phase of
the study, the Company intends to commence at the NIID a Phase 1b
adaptive-design, 200 patient, randomized, double-blinded,
controlled (2:1 TSC: placebo) study with enrollment and
patient observation targeted for completion in Q1 2021 and data
read-out in Q2 2021. In addition to safety and oxygenation markers,
the Phase 1b portion will include functional endpoints including
time-to-recovery through Day 28. Trial design and optimum endpoint
selection for final analyses are subject to modification based on
the interim data look in Q4 2020.
The Company intends to combine these results
with data from a planned similar U.S. trial to support the drug’s
possible approval in both Europe and the U.S. Based on
detailed U.S. Food and Drug Administration (FDA) guidance from a
Pre-IND Meeting Request response received last month, the Company
expects to file an Investigational New Drug (IND) application later
this month, with a response from the FDA expected on an accelerated
basis.
"Based on both preclinical and clinical data,
TSC has the potential to address the fatal oxygen deficiency that
can accompany COVID-19,” said Dr. Streinu-Cercel. "Given the
NAMMD’s regulatory acceleration program and more than 500 COVID-19
hospitalized patients here at the Institute, we expect timely
authorization, enrollment and data readout for the Phase 1a
portion, followed by a transition into the larger Phase 1b portion
of the study.”
“Rapid initiation and completion of the Phase 1a
portion of this trial should provide proof-of concept data in the
third quarter of this year,” said David Kalergis, chief executive
officer of Diffusion. “If favorable, we expect to immediately begin
the larger, randomized Phase 1b portion of the trial in Romania,
with continued support from the NIID and ARENSIA Exploratory
Medicine GmbH. Meanwhile, we are working with the University of
Virginia Health System, iTHRIV, the University of California Health
System and others for a timely start to the U.S. component of the
TSC clinical development plan in COVID-19, including filing of the
related IND with the FDA later this month.”
About TSC and COVID-19
Patients with COVID-19 respiratory tract
infections often present with significantly impaired oxygen levels.
Diffusion and its affiliated researchers believe the
oxygen-enhancing mechanism of action of TSC could benefit such
patients. Preclinical data indicate TSC increases oxygen
availability and provides a functional benefit in animal models of
acute lung injury and hemorrhagic shock. Clinical data from more
than 150 patients receiving TSC for other indications demonstrate
that the drug has an acceptable safety profile in both healthy and
critically ill patients.
About Diffusion Pharmaceuticals
Inc.
Diffusion Pharmaceuticals Inc. is an innovative
biotechnology company developing new treatments that improve the
body’s ability to deliver oxygen to the areas where it is needed
most, offering new hope for the treatment of life-threatening
medical conditions. Diffusion’s lead drug trans sodium crocetinate
(TSC) was originally developed in conjunction with the U.S. Office
of Naval Research, which was seeking a way to treat multiple organ
failure and its resulting mortality caused by low oxygen levels
from blood loss on the battlefield. Evolutions in research have led
to Diffusion’s focus today on addressing some of medicine’s most
intractable and difficult-to-treat diseases, including multiple
organ failure from respiratory distress, stroke and glioblastoma
multiforme (GBM) brain cancer. In each of these diseases, lack of
available oxygen presents a significant obstacle for medical
providers and is the target for TSC’s novel mechanism. The Company
is currently partnering with both U.S. and European-based
institutions in an expedited research program to develop TSC as a
treatment for the low oxygen levels and associated multiple organ
failure in COVID-19 patients.
In 2019, the Company reported favorable safety
data in a 19-patient dose-escalation run-in to its Phase 3 INTACT
program using TSC to target inoperable GBM. That trial is currently
paused while the Company prioritizes its resources to address
COVID-19. Diffusion’s in-ambulance PHAST-TSC trial for acute stroke
began enrolling patients last year. Given the heightened
responsibilities of the Company’s emergency medical services
providers, enrollment in this trial, while not officially paused,
is expected to be minimal until the COVID-19 pandemic abates.
Preclinical data supports the potential for TSC
as a treatment for other conditions where low oxygen availability
plays an important role, such as myocardial infarction, peripheral
artery disease, and neurodegenerative conditions such as
Alzheimer’s and Parkinson’s disease. In addition to the
development of TSC, RES-529, the Company’s PI3K/AKT/mTOR pathway
inhibitor that dissociates the mTORC1 and mTORC2 complexes, is in
preclinical testing for GBM.
Diffusion is headquartered in Charlottesville,
Virginia – a hub of advancement in the life science and
biopharmaceutical industries – and is led by CEO David Kalergis, a
30-year industry veteran and company co-founder.
Forward-Looking Statements
To the extent any statements made in this news
release deal with information that is not historical, these are
forward-looking statements under the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about the company's plans, objectives, expectations
and intentions with respect to future operations and products, the
potential of the company's technology and product candidates, and
other statements that are not historical in nature, particularly
those that utilize terminology such as "would," "will," "plans,"
"possibility," "potential," "future," "expects," "anticipates,"
"believes," "intends," "continue," "expects," other words of
similar meaning, derivations of such words and the use of future
dates. Forward-looking statements by their nature address matters
that are, to different degrees, uncertain. Uncertainties and risks
may cause the Diffusion’s actual results to be materially different
than those expressed in or implied by such forward-looking
statements. Particular uncertainties and risks include: the
uncertainty as to whether the FDA will approve the IND submission
for commencement of a trial in the U.S.; or that the FDA will not
require significant changes that might take significant time to
implement, if at all, or that any such required changes will be
financially feasible; there can be no assurance as to when the
program in the U.S. might be able to commence, if at all; the
uncertainty that as of yet the FDA has not approved a trial
evaluating TSC for the treatment of ARDS, or if approved, such a
trial possibly entailing significant additional time, effort and
expense, particularly in light of the difficulty of doing business
during the COVID-19 pandemic; the uncertainty as to whether the
protocol for the Romanian trial will be ultimately acceptable to
the Romanian healthcare regulatory authorities and local ethics
committees or that such regulators will not require significant
changes that might take significant time to implement, if at all,
or that any such required changes will be financially feasible;
moreover, if this or a revised protocol is acceptable to the
Romanian regulators, there can be no assurance as to when they
might provide such guidance or when the program might be able to
commence, if at all; the uncertainty that as of yet the Romanian
regulators have not approved a trial evaluating TSC for the
treatment of ARDS, or if approved, such a trial possibly entailing
significant additional time, effort and expense, particularly in
light of the difficulty of doing business during the COVID-19
pandemic; whether Diffusion can enroll and complete the trials and
provide data on the timelines indicated; whether Diffusion can
efficiently transition from the Phase 1a to Phase 1b portion of the
Romanian trials; whether the data from the Romanian trials can be
combined with data generated any U.S. trials; whether Diffusion has
sufficient funding to complete the trials described; Diffusion’s
ability to maintain its Nasdaq listing, market conditions, the
difficulty of developing pharmaceutical products, obtaining
regulatory and other approvals and achieving market acceptance;
general business and economic conditions; the company's need for
and ability to obtain additional financing or partnering
arrangements; and the various risk factors (many of which are
beyond Diffusion’s control) as described under the heading “Risk
Factors” in Diffusion’s filings with the United States Securities
and Exchange Commission. All forward-looking statements in this
news release speak only as of the date of this news release and are
based on management's current beliefs and expectations. Diffusion
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Contacts:David Kalergis, CEODiffusion Pharmaceuticals Inc.(434)
825-1834dkalergis@diffusionpharma.comorLHA Investor RelationsKim
Sutton Golodetz(212) 838-3777kgolodetz@lhai.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Apr 2023 to Apr 2024